



(51) International Patent Classification:

A61K 31/395 (2006.01) *A61K 31/44* (2006.01)*A61K 31/166* (2006.01) *A61K 31/33* (2006.01)

(21) International Application Number:

PCT/US2024/029839

(22) International Filing Date:

17 May 2024 (17.05.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/467,651 19 May 2023 (19.05.2023) US

63/612,533 20 December 2023 (20.12.2023) US

63/637,984 24 April 2024 (24.04.2024) US


(71) Applicant: **CIRCLE PHARMA, INC.** [US/US]; 681 Gateway Blvd., LGL 3rd Floor, South San Francisco, California 94080 (US).(72) Inventors: **BOCKUS, Andrew T.**; c/o Circle Pharma, Inc., 681 Gateway Blvd., LGL 3rd Floor, South San Francisco, California 94080 (US). **WALTON, Breana F.**; c/o Circle Pharma, Inc., 681 Gateway Blvd., LGL 3rd Floor, South San Francisco, California 94080 (US). **KREATSOULAS, Constantine**; c/o Circle Pharma, Inc., 681 Gateway Blvd., LGL 3rd Floor, South San Francisco, California 94080 (US). **AGGEN, James B.**; c/o Circle Pharma, Inc., 681 Gateway Blvd., LGL 3rd Floor, South San Francisco, California 94080 (US). **SHAPIRO, Justin A.**; c/o Circle Pharma, Inc., 681 Gateway Blvd., LGL 3rd Floor, South San Francisco, California 94080 (US). **DEMART, Megan**; c/o Circle Pharma, Inc., 681 Gateway Blvd., LGL 3rd Floor, South San Francisco, California 94080 (US). **DUPPER, Nathan**

J.; c/o Circle Pharma, Inc., 681 Gateway Blvd., LGL 3rd Floor, South San Francisco, California 94080 (US). **LEUNG, Sik Fai Siegfried**; c/o Circle Pharma, Inc., 681 Gateway Blvd., LGL 3rd Floor, South San Francisco, California 94080 (US). **BHATT, Chinmay**; c/o Circle Pharma, Inc., 681 Gateway Blvd., LGL 3rd Floor, South San Francisco, California 94080 (US). **METOBO, Samuel**; c/o Circle Pharma, Inc., 681 Gateway Blvd., LGL 3rd Floor, South San Francisco, California 94080 (US). **YANG, Kai**; c/o Circle Pharma, Inc., 681 Gateway Blvd., LGL 3rd Floor, South San Francisco, California 94080 (US). **HO, Ming Hsun**; c/o Circle Pharma, Inc., 681 Gateway Blvd., LGL 3rd Floor, South San Francisco, California 94080 (US). **SINGH, Rajinder**; c/o Circle Pharma, Inc., 681 Gateway Blvd., LGL 3rd Floor, South San Francisco, California 94080 (US). **BAMBAL, Ramesh B.**; c/o Circle Pharma, Inc., 681 Gateway Blvd., LGL 3rd Floor, South San Francisco, California 94080 (US).

(74) Agent: **DOLAN, Gregory F.** et al.; MINTZ, LEVIN, COHN, FERRIS, GLOVSKY AND POPEO, P.C., One Financial Center, Boston, Massachusetts 02111 (US).(81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(54) Title: CYCLIN INHIBITORS

Formula (I)



(57) **Abstract:** Disclosed herein are compounds of Formula (I), intermediates thereof, and methods for making the same : Formula (I). Also described herein are the use of such compounds and compositions for the treatment of diseases and disorders that are mediated, at least in part, by one or more cyclins, including cancer.

[Continued on next page]

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

- *with international search report (Art. 21(3))*